Shares of Agile Therapeutics Inc. (NASDAQ:AGRX) saw an uptick in trading volume on Tuesday . 161,240 shares changed hands during mid-day trading, an increase of 137% from the previous session’s volume of 68,151 shares.The stock last traded at $7.47 and had previously closed at $7.66.

Several research firms have issued reports on AGRX. Cantor Fitzgerald restated a “buy” rating on shares of Agile Therapeutics in a research note on Tuesday, May 31st. Zacks Investment Research lowered Agile Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, FBR & Co restated a “buy” rating on shares of Agile Therapeutics in a research note on Friday, June 17th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $15.17.

The stock’s market cap is $208.95 million. The firm has a 50-day moving average price of $7.52 and a 200 day moving average price of $6.79.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.11. Equities research analysts expect that Agile Therapeutics Inc. will post ($1.12) EPS for the current year.

An institutional investor recently raised its position in Agile Therapeutics stock. Marshall Wace LLP increased its position in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, Holdings Channel reports. The firm owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned 0.58% of Agile Therapeutics worth $1,267,000 at the end of the most recent reporting period.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.